Table 1.
Accuracy of diagnostic panels for NASH
| Reference | Biomarkers | N | AUROC | Cutoff value | Se (%) | Sp (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|---|---|---|---|
| Dixon [48] |
HAIR score |
105 |
0.90 |
score>2 |
80 |
89 |
n/a |
n/a |
| |
(hypertension, ALT>40 U/L, IR index>5) |
|
|
|
|
|
|
|
| Palekar [49] |
age≥50 years, female gender, AST≥45 U/L, |
80 |
0.76 |
score≥3 |
73.7 |
65.7 |
68.2 |
71.4 |
| |
BMI≥30 kg/m2, AAR ratio≥0.8, HA≥55 mcg/L |
|
|
|
|
|
|
|
| Poynard [50] |
NashTest |
257 |
0.78 |
n/a |
33 |
94 |
66 |
81 |
| |
(age, sex, height, weight, triglyceride, GGT, |
|
|
|
|
|
|
|
| |
cholesterol, alpha2macroglobulin, AST, ALT, |
|
|
|
|
|
|
|
| |
apolipoprotein A1, haptoglobin, total bilirubin) |
|
|
|
|
|
|
|
| Gholam [51] |
AST, presence of diabetes |
97 |
0.82 |
8.22 |
76 |
66 |
n/a |
n/a |
| Campos [52] |
NASH Clinical Scoring System for Morbid |
186 |
0.80 |
0-2 |
|
|
7 |
93 |
| |
obesity (hypertension, type 2 diabetes, |
|
|
3-4 |
|
|
27 |
73 |
| |
AST≥27 U/L, ALT ≥27 U/L, sleep apnea, |
|
|
5 |
|
|
59 |
41 |
| |
non-black race) |
|
|
6-7 |
|
|
93 |
7 |
| Ulitsky [53] |
diabetes, ALT >40 U/L, triglyceride >150 |
253 |
0.76 |
0-1 |
|
|
10.6 |
89.4 |
| |
mg/dL, sleep apnea |
|
|
2-3 |
|
|
24.7 |
75.3 |
| |
|
|
|
4 |
|
|
60 |
40 |
| |
|
|
|
5 |
|
|
75 |
25 |
| Shimada [54] |
adiponectin≤4 mcg/mL, HOMA-IR≥3, |
85 |
n/a |
all 3 +ive |
94 |
74 |
94 |
74 |
| |
type IV collagen 7S≥5 ng/mL |
|
|
|
|
|
|
|
| Tarek [56] |
CK18 fragments, sFas |
95 |
0.93 |
−0.5509 |
88 |
89 |
n/a |
n/a |
| Younossi [57] |
NASH Diagnostics |
101 |
0.908 |
0.2772 |
94.5 |
70.2 |
60 |
97.1 |
| |
(cleaved and intact CK18 levels, |
|
|
|
|
|
|
|
| |
serum adiponectin and resistin levels) |
|
|
|
|
|
|
|
| Sookoain [58] |
BMI, waist circumference, ALT, AST, AP, |
101 |
0.795 |
n/a |
n/a |
n/a |
n/a |
n/a |
| |
GGT, HOMA, CRP, sICAM-1 |
|
|
|
|
|
|
|
| Sumida [59] |
NAFIC score |
177† |
0.851† |
1 |
94 |
48 |
31 |
86 |
| |
[serum ferritin (≥200 ng/mL for female, |
|
|
2 |
66 |
91 |
90 |
67 |
| |
≥300 ng/mL for male), fasting insulin ≥10 |
442¥ |
0.782¥ |
1 |
88 |
43 |
66 |
75 |
| |
μU/mL, type IV collagen ≥5 ng/mL] |
|
|
2 |
60 |
87 |
85 |
64 |
| Younossi [60] |
NAFLD Diagnostic Panel |
79 |
0.81 |
0.221 |
91.2 |
47.4 |
60.8 |
85.7 |
| |
(diabetes, gender, BMI, triglycerides, |
|
|
0.3641 |
79.4 |
73.7 |
73 |
80 |
| apoptotic and necrotic CK18 fragments) | 0.6183 | 44.1 | 92.1 | 83.3 | 64.8 |
AUROC, area under receiver operator characteristic curve; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; ALT, alanine aminotransferase; IR, insulin resistance; AST, aspartate aminotransferase; BMI, body mass index; AAR, AST/ALT ratio; HA, hyaluronic acid; GGT, gamma-glutamyl transpeptidase; HOMA-IR, homeostasis model assessment of insulin resistance; AP, alkaline phosphatase; CRP, C-reactive protein; n/a, not available.
†Estimation group; ¥Validation group.